Regeneron Pharmaceuticals IncNASDAQ:REGN
- LAST PRICE828.4200
- TODAY'S CHANGE (%)3.9400 (0.4779%)
- Bid / Lots828.5000/ 1
- Ask / Lots855.0000/ 1
- Open / Previous Close826.5700 / 824.4800
- Day Range
- 52 Week Range
- Volume563,585
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | REGN |
|---|---|---|
| 09:32 ET | 6156 | 825.53 |
| 09:33 ET | 200 | 829.26 |
| 09:35 ET | 1232 | 826.14 |
| 09:37 ET | 100 | 826.89 |
| 09:39 ET | 400 | 827.97 |
| 09:42 ET | 1050 | 828.99 |
| 09:44 ET | 400 | 827.665 |
| 09:46 ET | 400 | 826.14 |
| 09:48 ET | 400 | 825.22 |
| 09:50 ET | 403 | 826.41 |
| 09:51 ET | 300 | 826.2 |
| 09:53 ET | 1336 | 825.525 |
| 09:55 ET | 1100 | 826.014 |
| 10:00 ET | 400 | 824.685 |
| 10:02 ET | 600 | 826.08 |
| 10:04 ET | 1814 | 825.515 |
| 10:06 ET | 1764 | 825.075 |
| 10:08 ET | 3072 | 825.31 |
| 10:09 ET | 875 | 823.405 |
| 10:11 ET | 746 | 822.96 |
| 10:13 ET | 2439 | 824.81 |
| 10:15 ET | 600 | 825.49 |
| 10:18 ET | 2614 | 825.99 |
| 10:20 ET | 763 | 825.445 |
| 10:22 ET | 1041 | 825.45 |
| 10:24 ET | 500 | 825.615 |
| 10:26 ET | 100 | 826.77 |
| 10:27 ET | 237 | 824.5 |
| 10:29 ET | 100 | 825.48 |
| 10:31 ET | 400 | 827.01 |
| 10:33 ET | 100 | 828.28 |
| 10:36 ET | 307 | 828.99 |
| 10:38 ET | 200 | 829 |
| 10:40 ET | 340 | 830 |
| 10:42 ET | 1625 | 830.73 |
| 10:45 ET | 131 | 829.99 |
| 10:47 ET | 100 | 829.99 |
| 10:51 ET | 200 | 829 |
| 10:54 ET | 1188 | 829.455 |
| 10:56 ET | 1683 | 828.98 |
| 11:00 ET | 100 | 828.07 |
| 11:03 ET | 458 | 826.87 |
| 11:05 ET | 700 | 827.24 |
| 11:07 ET | 2604 | 827.75 |
| 11:09 ET | 500 | 828.16 |
| 11:12 ET | 100 | 827.63 |
| 11:14 ET | 200 | 827.2493 |
| 11:16 ET | 200 | 828.22 |
| 11:18 ET | 900 | 828.5 |
| 11:20 ET | 1103 | 827.04 |
| 11:21 ET | 910 | 827.1255 |
| 11:23 ET | 500 | 826.81 |
| 11:25 ET | 900 | 827.195 |
| 11:27 ET | 922 | 826.185 |
| 11:30 ET | 500 | 825.32 |
| 11:32 ET | 8600 | 826.48 |
| 11:34 ET | 1628 | 825.72 |
| 11:36 ET | 100 | 825.71 |
| 11:39 ET | 1200 | 824.36 |
| 11:41 ET | 2200 | 824.875 |
| 11:43 ET | 3900 | 826.08 |
| 11:45 ET | 400 | 827.35 |
| 11:48 ET | 100 | 827.7 |
| 11:50 ET | 350 | 828.4 |
| 11:57 ET | 2254 | 828.61 |
| 11:59 ET | 200 | 827.98 |
| 12:01 ET | 150 | 827.474 |
| 12:12 ET | 4599 | 828.39 |
| 12:14 ET | 200 | 828.55 |
| 12:15 ET | 500 | 828.93 |
| 12:17 ET | 300 | 829.41 |
| 12:24 ET | 1852 | 828.59 |
| 12:26 ET | 300 | 828.15 |
| 12:28 ET | 600 | 827.37 |
| 12:30 ET | 406 | 826.9969 |
| 12:32 ET | 100 | 827.47 |
| 12:33 ET | 3577 | 828.605 |
| 12:35 ET | 558 | 829.915 |
| 12:37 ET | 839 | 829.56 |
| 12:39 ET | 122 | 829.965 |
| 12:42 ET | 532 | 829 |
| 12:46 ET | 574 | 829.25 |
| 12:48 ET | 1100 | 829.75 |
| 12:50 ET | 100 | 829.755 |
| 12:51 ET | 786 | 830.097778 |
| 12:53 ET | 4001 | 830.225 |
| 12:55 ET | 1150 | 829.785 |
| 12:57 ET | 850 | 828.111 |
| 01:00 ET | 300 | 829.5299 |
| 01:02 ET | 100 | 828.11 |
| 01:04 ET | 100 | 828 |
| 01:09 ET | 120 | 829.4652 |
| 01:11 ET | 100 | 828.74 |
| 01:13 ET | 1234 | 827.605 |
| 01:15 ET | 200 | 827.945 |
| 01:18 ET | 223 | 827.4007 |
| 01:22 ET | 700 | 827.06 |
| 01:24 ET | 100 | 827 |
| 01:26 ET | 355 | 827.5799 |
| 01:27 ET | 525 | 826.76 |
| 01:29 ET | 450 | 826.62 |
| 01:31 ET | 200 | 826.76 |
| 01:33 ET | 200 | 826.765 |
| 01:36 ET | 100 | 826.77 |
| 01:38 ET | 600 | 827.95 |
| 01:40 ET | 4379 | 826.46 |
| 01:42 ET | 220 | 826.69 |
| 01:44 ET | 1900 | 826.695 |
| 01:45 ET | 4390 | 826.33 |
| 01:47 ET | 750 | 827.265 |
| 01:49 ET | 2185 | 828.53 |
| 01:51 ET | 1886 | 828.445 |
| 01:54 ET | 6483 | 827.33 |
| 01:56 ET | 3217 | 827.12 |
| 01:58 ET | 3744 | 826.17 |
| 02:00 ET | 900 | 825 |
| 02:02 ET | 6129 | 822.98 |
| 02:03 ET | 200 | 824.45 |
| 02:05 ET | 400 | 825.27 |
| 02:07 ET | 920 | 825.885 |
| 02:09 ET | 100 | 826.06 |
| 02:12 ET | 1726 | 825.55 |
| 02:14 ET | 632 | 823.46 |
| 02:16 ET | 500 | 823.865 |
| 02:18 ET | 1500 | 823.865 |
| 02:20 ET | 785 | 824.315 |
| 02:21 ET | 413 | 824.84 |
| 02:23 ET | 100 | 825.09 |
| 02:25 ET | 1149 | 824.92 |
| 02:27 ET | 372 | 825.09 |
| 02:30 ET | 200 | 825.515 |
| 02:32 ET | 577 | 826.0401 |
| 02:34 ET | 631 | 825.495 |
| 02:36 ET | 376 | 825.455 |
| 02:38 ET | 900 | 824.81 |
| 02:39 ET | 745 | 826.59 |
| 02:41 ET | 400 | 827.14 |
| 02:43 ET | 2882 | 827.397956 |
| 02:45 ET | 100 | 827.02 |
| 02:48 ET | 200 | 827.66 |
| 02:50 ET | 476 | 827.04 |
| 02:54 ET | 300 | 826.54 |
| 02:56 ET | 200 | 826.601 |
| 02:57 ET | 1500 | 825.96 |
| 02:59 ET | 200 | 825.295 |
| 03:01 ET | 25340 | 825.24 |
| 03:03 ET | 6800 | 825.15 |
| 03:06 ET | 1200 | 825.285 |
| 03:08 ET | 4200 | 825.92 |
| 03:10 ET | 1900 | 826.475 |
| 03:12 ET | 100 | 827.29 |
| 03:14 ET | 462 | 828.096 |
| 03:15 ET | 204 | 828.944 |
| 03:17 ET | 100 | 828.3 |
| 03:19 ET | 3401 | 828.29 |
| 03:21 ET | 100 | 828.415 |
| 03:24 ET | 922 | 827.955 |
| 03:26 ET | 145 | 828.41 |
| 03:28 ET | 555 | 828.41 |
| 03:32 ET | 1887 | 828.49 |
| 03:33 ET | 1205 | 829 |
| 03:35 ET | 625 | 828.62 |
| 03:37 ET | 955 | 828.94 |
| 03:39 ET | 665 | 828.1718 |
| 03:42 ET | 200 | 828.675 |
| 03:44 ET | 1800 | 828.91 |
| 03:46 ET | 920 | 828.14 |
| 03:50 ET | 1400 | 828.36 |
| 03:51 ET | 2566 | 828.41 |
| 03:53 ET | 1405 | 827.71 |
| 03:55 ET | 6134 | 828.4 |
| 03:57 ET | 1901 | 830 |
| 04:00 ET | 109379 | 828.42 |
Nov 6, 2024
DJ Regeneron Pharma Is Maintained at Outperform by Oppenheimer, from 9:04AM ET on Wednesday Nov 06, 2024 by Dow Jones
9:04AM ET on Wednesday Nov 06, 2024 by Dow JonesDupixent(R) (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis, from 1:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
1:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 4, 2024
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 3:00PM ET on Monday Nov 04, 2024 by Dow Jones
3:00PM ET on Monday Nov 04, 2024 by Dow JonesINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 1:24PM ET on Monday Nov 04, 2024 by Dow Jones
1:24PM ET on Monday Nov 04, 2024 by Dow Jones
Nov 1, 2024
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 3:44PM ET on Friday Nov 01, 2024 by Dow Jones
3:44PM ET on Friday Nov 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regeneron Pharmaceuticals Inc | 91.0B | 20.5x | +10.93% |
Vertex Pharmaceuticals Inc | 133.1B | -259.4x | +46.35% |
IQVIA Holdings Inc | 39.8B | 28.8x | +46.62% |
Biogen Inc | 25.2B | 15.6x | -18.14% |
ICON PLC | 17.7B | 23.9x | +4.68% |
Moderna Inc | 18.0B | -8.1x | --- |
Company Information
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Contact Information
- Headquarters
- 777 Old Saw Mill River RoadTARRYTOWN, NY, United States 10591
- Phone
- 781-370-5000
- Fax
- ---
Executives
- Co-Chairman of the Board, President, Chief Executive Officer, Founder
- Leonard Schleifer
- Co-Chairman of the Board, President, Chief Scientific Officer
- George Yancopoulos
- Chief Financial Officer, Senior Vice President - Finance
- Christopher Fenimore
- Executive Vice President, General Counsel, Secretary
- Joseph LaRosa
- Executive Vice President, General Manager - Industrial Operations and Product Supply
- Daniel Van Plew
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $91.0B |
|---|---|
Revenue (TTM) | $13.8B |
Shares Outstanding | 109.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.11 |
EPS | $40.42 |
Book Value | $237.41 |
P/E Ratio | 20.5x |
Price/Sales (TTM) | 6.6 |
Price/Cash Flow (TTM) | 17.8x |
Operating Margin | 28.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
